Abbvie CDR (ABBV) Börsenkurse

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline PR Newswire NORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 Proposed acquisition adds Nimble's lead asset, an...

AbbVie Completes Acquisition of Aliada Therapeutics

AbbVie Completes Acquisition of Aliada Therapeutics PR Newswire NORTH CHICAGO, Ill., Dec. 11, 2024 Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease...

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell...

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease PR Newswire NORTH CHICAGO, Ill., Dec. 9, 2024 Tavapadon met...

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients PR Newswire NORTH CHICAGO, Ill., Dec. 8, 2024 -New insights show Black, Hispanic, and Asian...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PR...

AbbVie to Present at Citi's 2024 Global Healthcare Conference

AbbVie to Present at Citi's 2024 Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Nov. 25, 2024 NORTH CHICAGO, Ill., Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will...